Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 15Triple Negative Breast Neoplasms 9Neoplasms 8Prostatic Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Polycythemia Vera 1Pathologic Complete Response 1Osteosarcoma 1Neuroendocrine Tumors 1

Interventions

Paclitaxel 42Carboplatin 35pembrolizumab 25Surveys and Questionnaires 23Letrozole 15Radiotherapy 14Megestrol Acetate 14Blood Specimen Collection 14Bevacizumab 13olaparib 12Metformin 12dostarlimab 10Indocyanine Green 10durvalumab 9Observation 9Medroxyprogesterone Acetate 9Cisplatin 9lenvatinib 8atezolizumab 8Early Intervention, Educational 8Counseling 8niraparib 7Sentinel Lymph Node Biopsy 7Radiation 7Methods 7Magnetic Resonance Spectroscopy 7Lymph Node Excision 7Hysterectomy 7Everolimus 7abemaciclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Endometrial Neoplasms × talazoparib × Clear all
NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting
148 enrolled
Gynecologic

Endometrial Neoplasms

NCT03968406 2026-03-11

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
106 enrolled 16 charts
Gynecologic

Endometrial Neoplasms

NCT02127151 2021-08-06

PANDA

University College, London

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡